

Cleveland Clinic | ASCO 2025
Friday, May 30th

Time	Title	Session	Abstract/ Poster Number	Location
1:42 PM CDT	Dosing decitabine and venetoclax for terminal differentiation to improve outcomes in TP53 mutant MDS and AML.	Hematologic Malignancies— Leukemia, Myelodysplastic Syndromes, and Allotransplant	6514	E405a
4:57 PM CDT	INB-200: Phase 1 study of gene-modified autologous gamma-delta ($\gamma\delta$) t cells in newly diagnosed glioblastoma multiforme (GBM) patients receiving maintenance temozolomide (TMZ).	Central Nervous System Tumors	2007	S100bc
5:09 PM CDT	Results from the completed dose-finding part of phase 2 study of the innate cell engager acimtamig (AFM13) in combination with AlloNK (AB-101) in relapsed or refractory classical Hodgkin lymphoma (LuminICE-203).	Hematologic Malignancies— Lymphoma and Chronic Lymphocytic Leukemia	7008	S100a

Saturday, May 31st

Time	Title	Session	Abstract/ Poster Number	Location
8:36 AM CDT	Breast cancer diagnosis, management, and outcomes in transgender, nonbinary, and gender-diverse individuals: A multicenter cohort.	Care Delivery/Models of Care	1516	S402
9:00 AM – 12:00 PM CDT	Association between fine particulate matter exposure and colorectal cancer mortality by age at diagnosis: Insights from county-level analysis in the United States.	Gastrointestinal Cancer— Colorectal and Anal	3632 / 301	Hall A

9:00 AM – 12:00 PM CDT	Risk of intracranial hemorrhage with DOACs vs LMWH in patients with cancer-associated thrombosis and brain metastases.	Central Nervous System Tumors	2034 / 80	Hall A
9:00 AM – 12:00 PM CDT	Unveiling the role of sodium glucose cotransporter-2 inhibitors in hepatocellular carcinoma patients with cirrhosis: A comparative global cohort study.	Gastrointestinal Cancer— Gastroesophageal , Pancreatic, and Hepatobiliary	4138 / 428	Hall A
1:30 PM – 4:30 PM CDT	Association of radiomic features with disease-free survival following neoadjuvant chemoimmunotherapy in resectable NSCLC.	Lung Cancer - Non–Small Cell Local- Regional/Small Cell/Other Thoracic Cancers	8077 / 198	Hall A
1:30 PM – 4:30 PM CDT	Radiomic signatures as predictors of pathological response to neoadjuvant chemoimmunotherapy in surgically resected NSCLC.	Lung Cancer - Non–Small Cell Local- Regional/Small Cell/Other Thoracic Cancers	8080 / 201	Hall A
1:30 PM – 4:30 PM CDT	Disparities in NIH and federal cancer research funding across different cancer types.	Quality Care/Health Services Research	11025 / 364	Hall A
1:30 PM – 4:30 PM CDT	Evaluating the effectiveness of immersive virtual reality in reducing distress in patients with cancer receiving chemotherapy: A prospective randomized trial.	Quality Care/Health Services Research	11052 / 391	Hall A
3:39 PM CDT	Neoadjuvant pembrolizumab in combination with dabrafenib and trametinib (DTP) for BRAF V600E-mutated anaplastic thyroid cancer (BRAFM-ATC): A multicenter phase 2 trial.	Head and Neck Cancer	6008	S100a

4:06 PM CDT	Tirabrutinib for the treatment of relapsed or refractory primary central nervous system lymphoma: Efficacy and safety from the phase II PROSPECT study.	Central Nervous System Tumors	2019	S102
Sunday, June 1st				
Time	Title	Session	Abstract/Poster Number	Location
8:00 AM CDT	NRG-BR003: A randomized phase III trial comparing doxorubicin plus cyclophosphamide followed by weekly paclitaxel with or without carboplatin for node-positive or high-risk node-negative TNBC	Breast Cancer – Local/Regional/Adjuvant	LBA509	Hall B1
9:00 AM - 12:00 PM CDT	A phase Ib study to assess the safety and efficacy of autologous tumor infiltrating lymphocytes (lifileucel) with adjuvant pembrolizumab (PEMBRO) for treatment of immunotherapy naïve patients with high-risk clinical stage IIIb-d resectable melanoma (MEL).	Melanoma/Skin Cancers	TPS9611 / 84b	Hall A
9:00 AM - 12:00 PM CDT	Analysis of a large language model-based system versus manual review in clinical data abstraction and deduction from real-world medical records of patients with melanoma for clinical trial eligibility assessment.	Care Delivery/Models of Care	1571 / 337	Hall A
9:00 AM - 12:00 PM CDT	Long-term follow-up of the phase 2 ELM-2 study: Odronextamab for patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL)	Hematologic Malignancies — Lymphoma and Chronic Lymphocytic Leukemia	7049 / 232	Hall A
9:45 AM CDT	PRO-ACTIVE: Results of a pragmatic phase IV randomized trial comparing the effectiveness of prophylactic swallow intervention for patients receiving radiotherapy for head and neck cancer.	Symptom Science and Palliative Care	LBA1200 0	S100bc

10:09 AM CDT	Exploratory analysis of responders from the phase 3 EV-302 trial of enfortumab vedotin plus pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC).	Genitourinary Cancer — Kidney and Bladder	4502	Hall D2
11:30 AM CDT	Ficerafusp alfa with pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: Updated results from an expansion cohort of an open-label, multicenter, phase 1/1b trial.	Head and Neck Cancer	6017	E450a
11:45 AM CDT	Combination casdatifan plus cabozantinib expansion cohort of phase 1 ARC-20 study in previously treated patients with clear cell renal cell carcinoma.	Genitourinary Cancer — Kidney and Bladder	4506	Hall D2
12:42 PM CDT	Proposed changes to the pathologic staging for colon cancer (CC): AJCC Colon Cancer Expert Panel (AJCCCEP).	Gastrointestinal Cancer—Colorectal and Anal	3520	Hall D1
4:42 PM CDT	Intensified hormonal blockade with SBRT in PSMA-PET detected oligometastatic prostate adenocarcinoma: Results from the phase II Metacure trial cohorts B2 and the B2 expansion.	Genitourinary Cancer—Prostate, Testicular, and Penile	5014	Hall D2
Monday, June 2nd				
Time	Title	Session	Abstract/ Poster Number	Location
9:00 AM - 12:00 PM CDT	Fibroblast growth factor receptor 3 (FGFR3) alteration status and outcomes with immune checkpoint inhibitors (ICPI) in patients with metastatic urothelial carcinoma.	Genitourinary Cancer—Kidney and Bladder	4564 / 364	Hall A

9:57 AM CDT	Peri-transplant supportive and palliative care and/or comorbidity management for older, medically infirm, and/or frail recipients of allogeneic hematopoietic cell transplantation (Allo-HCT): Phase II and interim phase III trial analyses.	Symptom Science and Palliative Care	12011	E450a
10:12 AM CDT	Cognitive outcomes following proton vs. photon radiotherapy for CNS non-germinomatous germ cell tumors: A Children's Oncology Group study.	Pediatric Oncology	10061	S504
1:30 PM – 4:30 PM CDT	Inhaled KB707, a novel HSV-based immunotherapy, as a monotherapy in patients with advanced solid tumor malignancies affecting the lungs: Efficacy and safety results from a phase 1/2 study.	Developmental Therapeutics—Immunotherapy	2575 / 222	Hall A
1:30 PM – 4:30 PM CDT	Impact of body mass index on immunotherapy outcomes and complications in solid tumor patients: A real-world evidence analysis.	Developmental Therapeutics—Immunotherapy	2603 / 250	Hall A
Tuesday, June 3rd				
Time	Title	Session	Abstract/ Poster Number	Location
11:45 AM CDT	DREAMseq: A phase III trial of treatment sequences in BRAFV600-mutant (m) metastatic melanoma (MM)—Final clinical results.	Melanoma/Skin Cancers	9506	S100a
12:09 PM CDT	Safety and efficacy data from Nexicart-2, the first US trial of CAR-T in R/R light chain (AL) amyloidosis, Nxc-201.	Hematologic Malignancies—Plasma Cell Dyscrasia	7508	S100bc